. Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. J Comp Eff Res 2022. 11 621-637. DOI:https://doi.org/10.2217/cer-2022-0032.
View. Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release. EMBO Mol Med 2022. 14 14:e15919. DOI:https://doi.org/10.15252/emmm.202215919.
View. Olverembatinib: First Approval. Drugs February 2022. DOI:doi: 10.1007/s40265-022-01680-9. PMID: 35195876.
View. Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL). American Society of Hematology Annual Meeting 2021. Blood 2021; 138 (Supplement 1): 2062 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152207.
View. Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3598 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-153937.
View. Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 311 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-153065.
View. Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 2551. December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152693.
View. A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3730. December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152235.
View. A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3730 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152235.
View. Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 1554 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152811.
View. Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).. Presented at the Society for Immunotherapy of Cancer annual meeting 2021 Journal for ImmunoTherapy of Cancer 2021. . 9: Abstract 445 DOI:doi: 10.1136/jitc-2021-SITC2021.445.
View. Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome.. Presented at the Society for Immunotherapy of Cancer annual meeting 2021. Journal for ImmunoTherapy of Cancer 2021 November 10-14, 2021. 9: Abstract 450
View. Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM). Blood 2021; 138 (Supplement 1): 4764 November 5, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-151631.
View. Collaborative crosstalk between two apoptosis pathways drives synergy of dual inhibition of BCL-2/MDM2 in preclinical models of neuroblastoma [abstract]. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P209 Oct 7-10, 2021. DOI:https://doi.org/10.1158/1535-7163.TARG-21-P209.
View. Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia [abstract]. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 2021; 20(12 Suppl): Abstract nr P208. Oct 7-10, 2021. DOI:https://doi.org/10.1158/1535-7163.TARG-21-P208.
View. Phase 1b Study of Pelcitoclax (APG-1252) in combination with osimertinib in patients with EGFR TKI-resistant NSCLC Virtual. 2021 World Conference on Lung Cancer. Journal of Thoracic Oncology 2021 September 8-14, 2021. DOI:https://doi.org/10.1016/j.jtho.2021.08.115.
View. Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma. Presented at the American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology June 4-8, 2021. 39, no. 15_suppl: Abstract TPS6094
View. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. Oral presentation. Presented at the American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology June 4-8, 2021. no. 15_suppl: Abstract 2506 DOI:DOI: 10.1200/JCO.2021.39.15_suppl.2506.
View. Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC). American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology 39, no. 15_suppl: Abstract TPS8589 June 4-8, 2021.
View. First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs). American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology 39, no. 15_suppl: Abstract 7502 June 4-8, 2021. DOI:DOI: 10.1200/JCO.2021.39.15_suppl.7502.
View. Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation. The American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 968. April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-968.
View. Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors.. The American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract 1924 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1924.
View. Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN). American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract 984 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-984.
View. ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 1463 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1463.
View. FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML). American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 1096 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1096.
View. BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS) [abstract]. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract nr 981 Apr 10-15 and May 17-21, 2021. DOI:https://doi.org/10.1158/1538-7445.AM2021-981.
View. Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER+ breast cancer [abstract]. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl):Abstract nr 976. Apr 10-15 and May 17-21, 2021 . DOI:https://doi.org/10.1158/1538-7445.AM2021-976 .
View. A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. Abstract 20. Ann Oncol 2019. 30 (Supplement 1) i2-i3. DOI:10.1093/annonc/mdz027.
View. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd- generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia. American Society of Hematology Annual Meeting. Blood 2019; 134 (Supplement_1): 493. December 8, 2019. Abstract 493 DOI:doi: https://doi.org/10.1182/blood-2019-124295.
View. Phase I study of a novel Bcl-2 inhibitor, AT-101 in combination with lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM). American Society of Hematology Annual Meeting. Blood 2019; 134 (Supplement_1): 3137 December 8, 2019. Abstract 3137 DOI:doi: https://doi.org/10.1182/blood-2019-128610.
View. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer November 28, 2019. 7 327. DOI:10.1186/s40425-019-0750-6.
View. A novel BCL-2/BCL-Xl dual inhibitor overcomes ibrutinib-resistance conferred by the upregulation of integrin pathway and BCL-Xl. Blood 2019;134(Supplement 1): 2573 November 13, 2019. Abstract 2573
View. The inhibition of MDM2 by new antagonist APG-115 triggers apoptosis in p53 wild-type cancer cells in both in vitro and in vivo models. New Horizons in Cancer Research: Delivering Cures Through Cancer Science (AACR). . Poster presentation #2017
View. BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl): Abstract 2058. DOI:10.1158/1538-7445.AM2019-2058 .
View. A novel BCL-2/BCL-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma. Abstract 2054. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl) Abstract 2054. DOI:10.1158/1538-7445.AM2019-2054.
View. Predicting drug sensitivity to a novel BCL-2 and BCL-XL dual inhibitor in solid tumor PDX trials. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019: Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl) Abstract 2503. DOI:10.1158/1538-7445.AM2019-2503.
View. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. Abstract 3192. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA. Cancer Res July 1, 2019. 79(13 Suppl) Abstract 3192. DOI:10.1158/1538-7445.AM2019-3192.
View. A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. American Society of Clinical Oncology 2019 Annual Meeting. J Clin Oncol 2019;37(15 Suppl): Abstract 3124 June 1, 2019. DOI:DOI: 10.1200/JCO.2019.37.15_suppl.3124.
View. A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors. American Society of Clinical Oncology . J Clin Oncol 2019;37(15 Suppl):3125. NCT03386526 June 1, 2019. Abstract 3125
View. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. J Clin Oncol 2019;37(15 suppl): 3126. NCT02935907 May 26, 2019. Abstract 3126
View. A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. J Clin Oncol 2019. 37(15 Suppl): Abstract 3124. DOI:10.1200/JCO.2019.37.15_suppl.3124.
View. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. J Clin Oncol . 37(15 suppl). Abstract 3126 DOI:10.1200/JCO.2019.37.15_suppl.3126 .
View. A novel small molecule inhibitor of MDM2-p53 (APG-115) has antitumor activity in gastric adenocarcinoma. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting 2019. Cancer Res 2019;79(13 Suppl) March 29 to April 3, 2019. Abstract 2061
View. MDM2 inhibitor APG-115 synergizes with CDK4/6 inhibitors in a patient-derived xenograft model of dedifferentiated liposarcoma. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79 (13 Suppl) March 29 to April 3, 2019. Abstract 1253
View. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl) March 29 to April 3, 2019. Abstract 3192
View. FAK blockade enhances antitumor effect of BTK inhibitor in esophageal squamous cell carcinoma via EGFR-ERK-Akt pathway inhibition. American Association for Cancer Research Annual Meeting 2019. American Association for Cancer Research Annual Meeting March 31, 2019. 60:78-79 DOI:https://doi.org/10.1158/1538-7445.AM2019-309.
View. Synergistic effect of BCL-2 inhibitor APG-2575 and CDK9 inhibitor in acute myeloid leukemia and DLBCL preclinical tumor models. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl): Abstract 3068 DOI:10.1158/1538-7445.AM2019-3068 .
View. Predicting drug sensitivity to a novel BCL-2 and BCL-xL dual inhibitor in solid tumor PDX trials. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl): Abstract 2503 March 29 - April 3, 2019.
View. FAK inhibition reduces tumor infiltration of Tregs via restricting CCL5 release and boosts the present therapeutic regimen for BRAFV600E-mutated colorectal carcinoma. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl):Abstract 3958 March 29 - April 3, 2019 . DOI:https://doi.org/10.1158/1538-7445.AM2019-3958.
View. Novel FAK/ALK/ROS1 inhibitor APG-2449 synergizes with osimertinib in preclinical xenograft models of EGFR-mutant NSCLC. American Association for Cancer Research Annual Meeting 2019 . Cancer Res 2019;79(13 Suppl): Abstract 2204. March 29 - April 3, 2019. Poster Session PO. ET06-11. Abstract No. 19-A-2864. DOI:https://doi.org/10.1158/1538-7445.AM2019-2204.
View. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl): Abstract 3192. March 29 - April 3, 2019.
View. A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. European Society for Medical Oncology Targeted Anticancer Therapies International Congress 2019. Ann Oncol 2019;30 (Supplement 1):i2–i3 February 25-27, 2019. Abstract 20 DOI:doi: https://doi.org/10.1093/annonc/mdz027. NCT03611868.
View. Probing distinct oncogene addiction by novel BCL-2 inhibitors. 60th American Society of Hematology (ASH) Annual Meeting. Blood 2018;132(Suppl 1): 2616. Poster 2616 December 1-4, 2018.
View. Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: preliminary results of phase I study. 60th American Society of Hematology Annual Meeting. Blood 2018;132(Supplement 1):791. December 1-4, 2018.
View. Probing distinct oncogene addiction by novel BCL-2 inhibitors. 60th American Society of Hematology (ASH) Annual Meeting. Blood 2018;132(Suppl 1) December 1-4, 2018. Poster 2616 DOI:doi: https://doi.org/10.1182/blood-2018-99-119816.
View. A phase I study of novel BCL-2/BCL-XL inhibitor APG-1252 in patients with advanced SCLC or other solid tumor. Abstract OA12. J Thorac Oncol 2018. 132(Supplement 1) S1048-S1049. DOI:10.1016/j.jtho.2018.10.022.
View. Probing distinct oncogene addiction by novel BCL-2 inhibitors. Blood 2018. 132(Suppl 1) 2616. DOI:10.1182/blood-2018-99-119816 .
View. Probing distinct oncogene addiction by novel BCL-2 inhibitors. Blood November 29, 2018. 132(Suppl 1) Abstract 2616. DOI:10.1182/blood-2018-99-119816.
View. The SMAC mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma. Front Pharmacol 2018. 9 1298. DOI:10.3389/fphar.2018.01298.
View. Targeting cIAPs, a new option for functional cure of chronic hepatitis B infection. Virol Sin 2018. 33 459-461. DOI:10.1007/s12250-018-0062-x.
View. Inhibitors of anti-apoptotic BCL-2 family proteins are effective in non-Hodgkin’s lymphoma. Chinese Society of Clinical Oncology (CSC0) 18th annual meeting. .
View. The multi-faceted immunomodulatory function of Smac mimetic APG-1387 and its application in cancer immunotherapy. Chinese Society of Clinical Oncology (CSC0) 18th Annual Meeting. .
View. Inhibitors of anti-apoptotic BCL-2 family proteins are effective in non-Hodgkin’s lymphoma. Chinese Society of Clinical Oncology (CSC0) 18th Annual Meeting. .
View. Targeting BCL-2 and BCL-XL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models. Proceedings of the American Association for Cancer Research Annual Meeting; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl) Abstract 307. DOI:10.1158/1538-7445.AM2018-307.
View. Targeting the anti-apoptotic BCL-2 family protein provides an effective and precise therapeutic strategy for NHL. Proceedings of the American Association for Cancer Research Annual Meeting; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl) Abstract 301. DOI:10.1158/1538-7445.AM2018-301.
View. A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors. J Clin Oncol 2018. 36(15_suppl) 2593. DOI:10.1200/JCO.2018.36.15_suppl.2593 .
View. A phase I study of novel dual BCL-2/BCL-XL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. J Clin Oncol June 1, 2018. 36(Suppl 15) Abstract 2594. DOI:10.1200/JCO.2018.36.15_suppl.2594.
View. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of adenocarcinoma. J Exp Clin Cancer Res 2018. 37 97. DOI:10.1186/s13046-018-0765-8.
View. Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models. American Association for Cancer Research Annual Meeting 2018. Cancer Res 2018;78(13 Suppl): Abstract 1754 April 14-18, 2018.
View. A novel MDM2-p53 antagonist APG-115 induces p53-mediated apoptosis and enhances radiosensitivity in colorectal cancer. American Association for Cancer Research Annual Meeting. Cancer Res 2018;78(13 Suppl) April 14-18, 2018. Abstract 314
View. HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2018; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl): Abstract 1979 DOI:10.1158/1538-7445.AM2018-1979.
View. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res 2018. 37 53. DOI:10.1186/s13046-018-0703-9.
View. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells. Int J Oncol 2017;51:563-72 June 6, 2017.
View. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins BCL-2/BCL-xl in HL-60 cells. Int J Oncol 2017. 51 563-572. DOI:10.3892/ijo.2017.4028.
View. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. Oncotarget 2017. 8 43008-43022. DOI:10.18632/oncotarget.17398.
View. Discovery of 4‑((32R,42S,52R)‑63-Chloro-42-(3-chloro-2-fluorophenyl)12-ethyl-23-oxodispiro[cyclohexane-1,22-pyrrolidine-3′,33-indoline]52-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development. J Med Chem March 24, 2017. 60 2819-2839. DOI:10.1021/acs.jmedchem.6b01665.
View. A potent and highly efficacious bivalent Smac mimetic APG-1387 in phase I clinical development. 26th EORTC-NCI-AACR Symposium. . Poster 268
View. BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity. Eur J Cancer 2014:50:109-10 November 01, 2014. Poster 338
View. Preclinical studies of a dual BCL-2/BCL-XL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity. Abstract 544. Eur J Cancer 2014. 50(Suppl 6) 176-177. DOI:10.1016/S0959-8049(14)70670-7.
View